Pfizer CEO Albert Bourla (Drew Angerer/Getty Images)
Pfizer is on the verge of claiming a multibillion-dollar first-mover advantage with their Covid-19 vaccine — analyst
From the beginning, Pfizer CEO Albert Bourla eschewed government funding for his Covid-19 vaccine work with BioNTech, willing to take all the $2 billion-plus risk …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.